<?xml version='1.0' encoding='utf-8'?>
<document id="1551289"><sentence text="Fleroxacin clinical pharmacokinetics."><entity charOffset="0-10" id="DDI-PubMed.1551289.s1.e0" text="Fleroxacin" /></sentence><sentence text="Fleroxacin is a new member of the class of fluoroquinolones"><entity charOffset="0-10" id="DDI-PubMed.1551289.s2.e0" text="Fleroxacin" /></sentence><sentence text=" The drug has good activity (i" /><sentence text="e" /><sentence text=" minimum inhibitory concentrations at less than 2 mg/L against 90% of strains) against a wide range of Gram-positive and Gram-negative bacteria" /><sentence text=" High performance liquid chromatography is used to determine concentrations of fleroxacin and its metabolites in biological fluids"><entity charOffset="79-89" id="DDI-PubMed.1551289.s6.e0" text="fleroxacin" /></sentence><sentence text=" Absorption of orally ingested drug is rapid as the peak plasma concentration of approximately 5 mg/L is reached in 1 to 2h after a single dose of 400mg" /><sentence text=" The systemic availability is close to 100%" /><sentence text=" Fleroxacin is poorly bound to plasma proteins (23%) and exhibits excellent tissue distribution"><entity charOffset="1-11" id="DDI-PubMed.1551289.s9.e0" text="Fleroxacin" /></sentence><sentence text=" Renal clearance accounts for 60 to 70% of elimination" /><sentence text=" The drug is metabolised to form antimicrobially active N-demethyl-fleroxacin and inactive N-oxide-fleroxacin"><entity charOffset="56-77" id="DDI-PubMed.1551289.s11.e0" text="N-demethyl-fleroxacin" /><entity charOffset="99-109" id="DDI-PubMed.1551289.s11.e1" text="fleroxacin" /><pair ddi="false" e1="DDI-PubMed.1551289.s11.e0" e2="DDI-PubMed.1551289.s11.e0" /><pair ddi="false" e1="DDI-PubMed.1551289.s11.e0" e2="DDI-PubMed.1551289.s11.e1" /></sentence><sentence text=" In multiple dose studies the accumulation ratio of a once-daily dosage regimen is about 1" /><sentence text="3, as predicted from the elimination half-life of 10 to 12h" /><sentence text=" Compared with ciprofloxacin, fleroxacin has a greater systemic availability and a longer half-life"><entity charOffset="15-28" id="DDI-PubMed.1551289.s14.e0" text="ciprofloxacin" /><entity charOffset="30-40" id="DDI-PubMed.1551289.s14.e1" text="fleroxacin" /><pair ddi="false" e1="DDI-PubMed.1551289.s14.e0" e2="DDI-PubMed.1551289.s14.e0" /><pair ddi="false" e1="DDI-PubMed.1551289.s14.e0" e2="DDI-PubMed.1551289.s14.e1" /></sentence><sentence text=" Fleroxacin concentrations are higher in elderly patients, but further studies are needed to establish whether a dosage reduction should be recommended for this age group"><entity charOffset="1-11" id="DDI-PubMed.1551289.s15.e0" text="Fleroxacin" /></sentence><sentence text=" In patients with renal disease dosage adjustment is recommended since a decreased renal clearance of fleroxacin leads to a significant prolongation of the elimination half-life"><entity charOffset="102-112" id="DDI-PubMed.1551289.s16.e0" text="fleroxacin" /></sentence><sentence text=" Fleroxacin is only poorly eliminated by peritoneal dialysis or haemodialysis"><entity charOffset="1-11" id="DDI-PubMed.1551289.s17.e0" text="Fleroxacin" /></sentence><sentence text=" The most important drug-drug interaction is a decrease in systemic availability of fleroxacin after ingestion of aluminium- or magnesium-containing antacids"><entity charOffset="84-94" id="DDI-PubMed.1551289.s18.e0" text="fleroxacin" /><entity charOffset="128-137" id="DDI-PubMed.1551289.s18.e1" text="magnesium" /><pair ddi="false" e1="DDI-PubMed.1551289.s18.e0" e2="DDI-PubMed.1551289.s18.e0" /><pair ddi="false" e1="DDI-PubMed.1551289.s18.e0" e2="DDI-PubMed.1551289.s18.e1" /></sentence><sentence text=" There is no evidence of a significant interaction between fleroxacin and theophylline"><entity charOffset="59-69" id="DDI-PubMed.1551289.s19.e0" text="fleroxacin" /><entity charOffset="74-86" id="DDI-PubMed.1551289.s19.e1" text="theophylline" /><pair ddi="false" e1="DDI-PubMed.1551289.s19.e0" e2="DDI-PubMed.1551289.s19.e0" /><pair ddi="false" e1="DDI-PubMed.1551289.s19.e0" e2="DDI-PubMed.1551289.s19.e1" /></sentence><sentence text=" Only limited data are available on adverse reactions of fleroxacin"><entity charOffset="57-67" id="DDI-PubMed.1551289.s20.e0" text="fleroxacin" /></sentence><sentence text=" The most important adverse effects appear to be photosensitivity and a dose-dependent incidence of central nervous system reactions including sleep disorders" /><sentence text="" /></document>